127 related articles for article (PubMed ID: 15622611)
21. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
Dearnaley DP; Khoo VS; Norman AR; Meyer L; Nahum A; Tait D; Yarnold J; Horwich A
Lancet; 1999 Jan; 353(9149):267-72. PubMed ID: 9929018
[TBL] [Abstract][Full Text] [Related]
22. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
[TBL] [Abstract][Full Text] [Related]
23. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
[TBL] [Abstract][Full Text] [Related]
24. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
Matzinger O; Poortmans P; Giraud JY; Maingon P; Budiharto T; van den Bergh AC; Davis JB; Musat E; Ataman F; Huyskens DP; Gulyban A; Bolla M;
Radiother Oncol; 2009 Mar; 90(3):285-90. PubMed ID: 19038468
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
26. Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy.
Sandler HM; Perez-Tamayo C; Ten Haken RK; Lichter AS
Radiother Oncol; 1992 Jan; 23(1):53-4. PubMed ID: 1736332
[TBL] [Abstract][Full Text] [Related]
27. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
28. [New methods in the treatment of localized prostate cancer: use of dynamic arc therapy and kV cone-beam CT positioning].
Szappanos S; Farkas R; Lőcsei Z; László Z; Kalincsák J; Bellyei S; Sebestyén Z; Csapó L; Sebestyén K; Halász J; Musch Z; Beöthe T; Farkas L; Mangel L
Orv Hetil; 2014 Aug; 155(32):1265-72. PubMed ID: 25087218
[TBL] [Abstract][Full Text] [Related]
29. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
30. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer.
Roach M
Urol Clin North Am; 2004 May; 31(2):353-66. PubMed ID: 15123413
[TBL] [Abstract][Full Text] [Related]
31. The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer.
De Meerleer GO; Villeirs GM; Vakaet L; Delrue LJ; De Neve WJ
Strahlenther Onkol; 2004 Sep; 180(9):573-81. PubMed ID: 15378188
[TBL] [Abstract][Full Text] [Related]
32. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
[TBL] [Abstract][Full Text] [Related]
33. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
Valicenti RK; Winter K; Cox JD; Sandler HM; Bosch W; Vijayakumar S; Michalski J; Purdy J
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):614-20. PubMed ID: 14529764
[TBL] [Abstract][Full Text] [Related]
34. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review.
Brundage M; Lukka H; Crook J; Warde P; Bauman G; Catton C; Markman BR; Charette M;
Radiother Oncol; 2002 Sep; 64(3):239-50. PubMed ID: 12242112
[TBL] [Abstract][Full Text] [Related]
35. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
Bruner DW; Hunt D; Michalski JM; Bosch WR; Galvin JM; Amin M; Xiao C; Bahary JP; Patel M; Chafe S; Rodrigues G; Lau H; Duclos M; Baikadi M; Deshmukh S; Sandler HM
Cancer; 2015 Jul; 121(14):2422-30. PubMed ID: 25847819
[TBL] [Abstract][Full Text] [Related]
36. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
37. Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).
Stanley S; Griffiths S; Sydes MR; Moore AR; Syndikus I; Dearnaley DP;
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):582-90. PubMed ID: 18565744
[TBL] [Abstract][Full Text] [Related]
38. Analysis of dose distribution in the 'Rind'--a volume outside the PTV--in 3-dimensional conformal radiation therapy of non-small cell lung cancer.
McGibney C; Holmberg O; McClean B; Armstrong J
Radiother Oncol; 2003 Jan; 66(1):87-93. PubMed ID: 12559525
[TBL] [Abstract][Full Text] [Related]
39. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer.
Martinez AA; Yan D; Lockman D; Brabbins D; Kota K; Sharpe M; Jaffray DA; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1226-34. PubMed ID: 11483333
[TBL] [Abstract][Full Text] [Related]
40. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy.
Wu VW; Kwong DL; Sham JS
Radiother Oncol; 2004 May; 71(2):201-6. PubMed ID: 15110454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
